Clinical Trial Update: Expanded Access to Upadacitinib

View source ↗

Summary

AbbVie’s expanded access program for Upadacitinib is currently AVAILABLE for patients with Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis (i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Crohn Disease
• Juvenile Idiopathic Arthritis
• Ulcerative Colitis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Crohn Disease, Ulcerative Colitis | Status: AVAILABLE